Abstract: This disclosure is related to methods of objectively detecting and measuring neuropathic pain in a subject.

Abstract: Technologies for the prevention and/or treatment of pneumococcal infections.

Abstract: The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.

Abstract: An ongoing pain detection system and method are provided. The method includes obtaining imaging data from patient using functional near-infrared spectroscopy from at least one cortical region of the brain of a non-responsive patient and observing power spectral density variations in the signal. The measured imaging data is compared with patient pain based on control data to recognize ongoing pain in the non-responsive patient.

Abstract: Products, such as devices, prostheses, and materials, whose surfaces have been modified in order to impart beneficial properties to these products are disclosed. The surface-modified products have improved biocompatibility compared to a corresponding product that lacks the modification. Following implantation in a subject, the surface-modified products induce a lower foreign-body response, compared to a corresponding unmodified product.

Abstract: Methods, systems, and cooptation measurement devices as described herein include an elongate sensor body at the end of a proximal connecting member, and a plurality of sensors in an array across a face of the sensor body, wherein each sensor of the plurality of sensors is configured to detect if a portion of a heart valve is in contact with the sensor.

Abstract: Provided herein, inter alia, are improved methods for detecting analytes, including proteins and nucleic acids. In some instances, the analytes are detected in complex matrices such as serum.

Abstract: Provided herein are uses for an immunostimulatory compound for stimulating an immune response when administered either alone or as an adjuvant in a vaccine. Also provided herein are kits, compositions, and methods of administration for the compound described.

Abstract: The present invention provides compositions and methods for treating a myopathy. In certain embodiments, the invention provides compositions and methods for treating, improving muscle function, and prolonging survival in a subject with X-linked myotubular myopathy (XLMTM). The present invention provides a method comprising systemic administration of a composition that induces the increased expression of myotubularin in the muscle of a subject. The invention provides sustained regional and global increases in muscle function.

Abstract: The invention provides methods for activating a repressed allele within an imprinting control region, thereby treating an imprinting associated disorder.

Abstract: The present embodiments provide for an immunogenic multiple antigen presenting system comprising a polymer to which antigens are associated by complementary affinity molecules. For example, the polymer can be a polysaccharide, or antigenic polysaccharide, to which protein or peptide antigens from the same or different pathogens are indirectly linked. The present immunogenic compositions can elicit both humoral and cellular immune responses to one or multiple antigens at the same time.

Abstract: This disclosure relates to methods and compositions useful for detecting and monitoring low-frequency mutations. Methods and compositions described herein can be used to guide clinical decisions, for example, by informing on which antibiotics should be avoided, or conversely, which antibiotics should be actively used in the case of compounds that select against a specific type of resistance.

Abstract: The disclosure relates to compounds that are, e.g., PAP Associated Domain Containing 5 (PAPD5) inhibitors and methods of use thereof.

Abstract: The technology described herein relates to compositions and methods of generating endothelial niche cells. Embodiments of the technology described herein comprise compositions, kits, vectors, and methods related to generating or engineering endothelial niche cells. One aspect comprises a method to generate/engineer endothelial niche cells, comprising expressing one or more transcription factors in an endothelial cell, wherein the one or more transcription factors are from the Ets family, the Sox family, and/or the Nuclear Hormone (NHR) family.

Abstract: The disclosure relates to compositions comprising isolated mitochondria or combined mitochondrial agents, and methods of treating disorders using such compositions.

Abstract: An electrocautery device with a retractable suction tube is described. The electrocautery device includes a suction tube assembly that can move between an extended or retracted position using vacuum force generated by a suction source. In some embodiments, the suction tube assembly automatically locks into the extended position when extended such that axial force cannot cause the suction tube assembly to retract. The device may be suitable for use in laparoscopic procedures. The suction tube may be coaxially aligned with the electrocautery tip.

Abstract: The present invention provides compositions and methods for targeting cells for therapeutic and/or diagnostic purposes, e.g., delivery of therapeutic and/or diagnostic agents to a cell. Nanoparticles and polymers functionalized with capture molecules, reporter molecules, and/or therapeutic agents are provided for the treatment or prevention of disease, including neurological diseases associated with neuroinflammation, and cancer.

Abstract: Described herein are methods and compositions for treating cancer. Aspects of the invention relate to administering to a subject having cancer an inhibitor of the super elongation complex (SEC). In various embodiments, the cancer is a blood cancer. Wherein the blood cancer is selected from the group consisting of leukemia, lymphoma, myeloma, and myeloproliferative neoplasms (MPNs).

Abstract: Disclosed herein are non-myeloablative antibody-toxin conjugates and compositions that target cell surface markers, such as the CD34, CD45 or CD117 receptors, and related methods of their use to effectively conditioning a subject's tissues (e.g., bone marrow tissue) prior to engraftment or transplant. The compositions and methods disclosed herein may be used to condition a subject's tissues in advance of, for example, hematopoietic stem cell transplant and advantageously such compositions and methods do not cause the toxicities that are commonly associated with traditional conditioning methods.

Abstract: A method of detecting the likelihood of a seizure event in a patient includes at successive expirations of a first time interval, determining a first likelihood that the patient is experiencing a seizure based on electrodermal activity and a movement of a limb of the patient. The method also includes at successive expirations of a second time interval, determining whether the patient experienced a seizure in a second time period preceding the determining based on a heart rate of the patient. In response to determining that the third comparison result satisfies at least a third detection criterion, the method compares electrodermal activity and the movement of a limb of the patient to determine a second likelihood. In response to determining that the second likelihood satisfies a second detection criterion, the method triggers presentation of a second alert regarding a potential seizure.